DiscGenics Injectable Disc Cell Therapy (IDCT)

Overview of DiscGenics Injectable Disc Cell Therapy

DiscGenics Injectable Disc Cell (IDCT, or rebonuputemcel) is a first-in-class, allogeneic, injectable cell therapy that uses disc-derived progenitor cells to biologically repair damaged intervertebral discs. It is designed to treat symptomatic lumbar degenerative disc disease (DDD) in patients who are not surgical candidates but continue to suffer from chronic pain and impaired function.

1. Upcoming Phase III Clinical Trials: PIVOT and CONFIRM

DiscGenics is preparing to launch two large-scale, Phase III clinical trials in the United States to further evaluate the safety and efficacy of IDCT:

• PIVOT Trial (DGX-A02): This is the pivotal study designed to serve as the primary efficacy and safety evaluation. It will determine whether DiscGenics Injectable Disc Cell therapy provides significant improvements in pain relief, physical function, and disc morphology.
• CONFIRM Trial (DGX-A03): This confirmatory trial will run concurrently and is intended to replicate the findings of the PIVOT study in an independent, randomized cohort.

Both trials are designed to the highest clinical standards: they are randomized, double-blinded, sham-controlled, and multicenter in design. This means patients will be randomly assigned to receive either the IDCT treatment or a sham procedure, and neither the patient nor the investigator will know which was given. These rigorous protocols ensure unbiased, reliable results.

The trials will specifically enroll adult patients with single-level, symptomatic lumbar DDD. Multicenter participation ensures geographic and demographic diversity, increasing the generalizability of outcomes. Subject enrollment is expected to begin in the second quarter of 2025.

2. Previous First-in-Human Studies

Prior to the Phase III programs, DiscGenics successfully completed two first-in-human clinical studies evaluating IDCT:

• United States Phase I/II Study: This prospective, randomized, double-blinded, and placebo-controlled trial demonstrated significant improvements in back pain scores, disability indices, and disc volume on imaging. Benefits were maintained for up to 2 years post-injection.
• Japanese Clinical Study: Conducted independently, this study confirmed consistent outcomes among a different population, validating the global potential of DiscGenics Injectable Disc Cell therapy. The parallel success between U.S. and Japan has laid the groundwork for international expansion.

3. Accelerated Regulatory Pathways: RMAT and Fast Track

The U.S. Food and Drug Administration (FDA) has granted multiple expedited review designations for IDCT:

• RMAT (Regenerative Medicine Advanced Therapy): This designation is awarded to regenerative therapies that show early promise in treating serious conditions. It provides benefits such as rolling review and increased guidance from FDA staff.
• Fast Track Status: This further accelerates the timeline by allowing more frequent communications and streamlined submission procedures.
• Breakthrough Device Designation: IDCT is the only spine-related cell therapy to receive this status, highlighting its potential to address a major unmet need in lumbar disc degeneration treatment.

These designations place DiscGenics Injectable Disc Cell therapy on a uniquely rapid path toward possible FDA approval and market access.

4. Manufacturing, Cell Purity, and Delivery

IDCT is manufactured under current Good Manufacturing Practices (cGMP), ensuring product consistency, sterility, and cell viability. The progenitor cells are isolated from donated human intervertebral disc tissue, cultured under proprietary protocols, and cryopreserved for on-demand use.

The product is injected directly into the nucleus pulposus of the degenerated disc using fluoroscopic image guidance. This outpatient procedure takes less than 30 minutes and does not require sedation or general anesthesia.

Once delivered, the Discogenic Cells respond to the inflammatory microenvironment of the degenerated disc by secreting bioactive molecules that reduce inflammation, stimulate matrix repair, and encourage rehydration of the disc space.

5. How It Differs from PRP and Wharton’s Jelly

PRP (platelet-rich plasma) is derived from a patient’s own blood and is used to reduce inflammation. While PRP is helpful in mild DDD, it lacks the ability to regenerate disc tissue. Wharton’s Jelly, harvested from umbilical cord tissue, provides growth factors and mesenchymal cells but is used off-label and lacks FDA-recognized clinical trials for disc-specific use.

6. How DiscGenics Injectable Disc Cell Differs from ViaDisc

While both DiscGenics Injectable Disc Cell (IDCT) and ViaDisc are injectable therapies for degenerative disc disease, they differ significantly in origin, composition, and clinical validation.

• Source of Cells: IDCT uses live, allogeneic disc progenitor cells derived from donated human disc tissue. In contrast, ViaDisc contains dehydrated allograft material without live cells, designed to supplement disc hydration and volume.
• Biologic Activity: IDCT includes viable cells capable of actively modulating inflammation and promoting matrix repair. ViaDisc works more passively as a structural scaffold.
• Regulatory Path: IDCT has been granted FDA Breakthrough Device and RMAT designations, with Phase III trials under FDA oversight. ViaDisc does not have these designations and has not undergone placebo-controlled pivotal studies to date.
• Purpose-Built for Disc Regeneration: DiscGenics developed IDCT specifically for disc repair, while ViaDisc is often used as an augmentation product without a direct regenerative mechanism.

Patients exploring regenerative spine treatments should understand these differences before selecting an intradiscal option. Our practice offers both solutions where clinically appropriate and explains them during consultation.

To learn more about IDCT and its development, visit the official DiscGenics website.